293780 — AptaBio Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for AptaBio Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS/A	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	341	224	48.4	324	3,361
Cost of Revenue
Gross Profit	—	—	—	78.5	287
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	6,406	11,591	9,555	16,697	22,215
Operating Profit	-6,065	-11,367	-9,507	-16,374	-18,854
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3,919	-10,689	-10,565	-14,692	-27,803
Provision for Income Taxes
Net Income After Taxes	-3,919	-10,689	-10,565	-12,062	-29,378
Net Income Before Extraordinary Items
Net Income	-3,919	-10,689	-10,565	-12,062	-29,378
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-3,919	-10,689	-10,565	-11,866	-29,378
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-178	-712	-474	-532	-1,248
Dividends per Share